Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension (PRISMA-3_OLE)

• ClinicalTrials.gov Identifier: NCT03870880
• Recruitment Status: Completed
• First Posted: March 12, 2019
• Results First Posted: February 23, 2022
• Last Update Posted: February 23, 2022
• Sponsor: Rovi Pharmaceuticals Laboratories
• Information provided by (Responsible Party): Rovi Pharmaceuticals Laboratories

Study Description

Brief Summary:

This is the long-term open label extension (OLE) of the study PRISMA-3 (NCT03160521). Those patients who complete participation in the main segment of the study (double blind) together with other clinically stable not previously enrolled (de novo patients) may opt to participate in this extension segment, where they will receive active Risperidone ISM® (75 mg or 100 mg)under open-label conditions every four weeks for approximately 12 months.

Condition or disease	Intervention/treatment	Phase
Schizophrenia	Drug: Risperidone ISM 75 mg; Drug: Risperidone ISM 100 mg	Phase 3

Detailed Description:

Patients who have completed planned participation in the double-blind segment of the study PRISMA-3 (NCT03160521) through to the end of the treatment period, may be eligible to enter into this optional long-term extension segment of the study. During this extension, open-label Risperidone ISM® (i.e., either 75 or 100 mg) will be administered to all participating patients once every 4 weeks for approximately 12 months. Patients who enter into the extension segment of the study will begin participation in the extension segment immediately upon completion of the end-of-treatment visit assessments and procedures.

In addition to patients continuing from the double-blind segment of the study PRISMA-3 (rollover patients), clinically stable patients not previously enrolled in the study (de novo patients) may be eligible to enter the long-term extension segment of the study. These patients will be evaluated for eligibility at a screening visit and, if eligible, will be allocated to receive either 75 or 100 mg Risperidone ISM every 4 weeks for approximately 12 months.

Approximately 100 de novo patients are planned to be enrolled in the extension segment of the study, in addition to rollover patients.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 215 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Masking Description: It is an open label extension
• Primary Purpose: Treatment
• Official Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia: Open Label Extension (PRISMA-3_OLE)
• Actual Study Start Date: August 25, 2017
• Actual Primary Completion Date: January 8, 2020
• Actual Study Completion Date: January 8, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Risperidone ISM 75 mg; Patients assigned to this arm will receive 75 mg of Risperidone ISM during the open label extensión (OLE). Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients.	Drug: Risperidone ISM 75 mg; Monthly (once every 4 weeks) intramuscular (IM) injection in the gluteal or deltoid muscle.
Experimental: Risperidone ISM 100 mg; Patients assigned to this arm will receive 100 mg of Risperidone ISM during the open label extensión (OLE). Patients enter the study as rollover patients from the study NCT03160521, along with newly enrolled de novo patients.	Drug: Risperidone ISM 100 mg; Monthly (once every 4 weeks) IM injection in the gluteal or deltoid muscle.

Outcome Measures

Primary Outcome Measures :

1. PANSS Total Score Mean Change From Baseline to Endpoint [ Time Frame: Day 365 (or the last post-baseline assessment) ]

   The Positive and Negative Syndrome Scale (PANSS) is a 30-item clinician-rated instrument for assessing the symptoms of schizophrenia.The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score is the sum of all 30 PANSS items and ranges from 30 to 210, with 30 indicating absence of symptoms of schizophrenia and 210 indicating extreme ratings of all 30 symptoms. Negative change from baseline scores indicates improvements in symptoms whereas higher scores mean a worse outcome.

   Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.

Other Outcome Measures:

1. PANSS Positive Subscale Mean Change From Baseline to Endpoint [ Time Frame: Day 365 (or the last post-baseline assessment) ]

   The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility.

   PANSS Positive Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

   Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.

2. PANSS Negative Subscale Mean Change From Baseline to Endpoint [ Time Frame: Day 365 (or the last post-baseline assessment) ]

   The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated- absence of symptoms and a score of 7 indicated- extremely severe symptoms. The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs were: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. PANSS Negative Subscale Score ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

   Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.

3. PANSS General Psychopathology Subscale Mean Change From Baseline to Endpoint [ Time Frame: Day 365 (or the last post-baseline assessment) ]

   The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The general psychopathology scale consists of 16 items which measure somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance. PANSS General Psychopathology Subscale Score ranges from 16 (absence of symptoms) to 112 (extremely severe symptoms).

   Endpoint is defined as study day 356 or the last post-baseline assessment if early discontinuation.

4. Clinician Global Impression - Severity (CGI-S) Total Score Mean Change From Baseline to Endpoint [ Time Frame: Day 365 (or the last post-baseline assessment) ]

   The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome.

   Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.

5. Clinician Global Impression - Improvement (CGI-I) Score [ Time Frame: Day 365 (or the last post-baseline assessment) ]

   The Clinical Global Impression - Improvement (CGI-I) is a single 7-point rating score total improvement, regardless of whether or not the change it is due entirely to drug treatment. Raters select one response based on the following question, "Compared to your patient's condition at the beginning of treatment, how much has your patient changed?" Scores are: 1, Very much improved; 2, Much improved; 3, Minimally improved; 4, No change; 5, Minimally worse; 6, Much worse; or 7, Very much worse.

   Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.

6. Overall Response Rate at Endpoint [ Time Frame: Day 365 (or the last post-baseline assessment) ]

   Overall response was defined as either PANSS total score ≥ 30% decrease from baseline, or CGI-I score of 2 (much improved) or 1 (very much improved).

   Endpoint is defined as study day 365 or the last post-baseline assessment if early discontinuation.

7. Relapse Rate [ Time Frame: Day 365 (or the last post-baseline assessment) ]
   Relapse was defined as either increase from baseline in PANSS total score ≥30% or rehospitalization for psychotic symptoms or use of adjunctive antipsychotic medication after stabilization.
8. Patients With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: Up to Day 365 (or the last post-baseline assessment) ]

   An Adverse event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study (from the informed consent form signature) or, if present at screening, worsens during the study, regardless of the suspected cause of the event.

   The treatment-emergent AEs (TEAEs) are defined as events that are newly occurring or worsening from the time of the first dose of the intramuscular study drug.

9. TEAEs Leading to Study Drug Discontinuation [ Time Frame: Up to Day 365 (or the last post-baseline assessment) ]
   TEAEs which resulted in permanent study drug discontinuation
10. Patients With Treatment-related TEAEs [ Time Frame: Up to Day 365 (or the last post-baseline assessment) ]

    An Adverse event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study (from the informed consent form signature) or, if present at screening, worsens during the study, regardless of the suspected cause of the event.

    The treatment-emergent AEs (TEAEs) are defined as events that are newly occurring or worsening from the time of the first dose of the intramuscular study drug.

    The temporal relationship of the AE with the investigational medicinal product makes causality possible, and the AE cannot be due to another cause such as other drugs, a surgical intervention, or an underlying disease

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Participation in the open-label extension segment of the study PRISMA-3 is optional, and patients who complete participation in the main segment of the study (double blind segment of PRISMA-3, NCT03160521) may opt to not participate. Patients who are interested in participating must meet all eligibility criteria in order to enter into the extension segment.

Inclusion Criteria (Rollover patients):

To be eligible for entry into the extension segment of the study PRISMA-3, a patient must meet all of the following criteria at the extension baseline time point (immediately upon completion of the end-of-treatment visit assessments and procedures for the main part of the study):

1. Has completed scheduled participation in the double blind segment of the study PRISMA-3, through to the end of the treatment period and including the end-of-treatment visit
2. Continues to require long-term treatment with an antipsychotic medication, in the opinion of the investigator
3. Continues to meet contraceptive requirements of the study PRISMA-3

4. Is willing to participate in the extension segment of the study and remains capable of providing informed consent

   a. A signed informed consent form must be provided before any study assessments are performed for the extension segment

5. Continues to reside in a stable living situation, in the opinion of the investigator
6. Continues to have an identified reliable informant, in the opinion of the investigator

Exclusion Criteria (Rollover patients):

An individual who meets any of the following criteria at the extension baseline time point (immediately upon completion of the end-of-treatment visit assessments and procedures for the double blind segment PRISMA-3) will not be permitted to enter into this extension segment of the study PRISMA-3:

1. Missed more than 1 scheduled study visit during participation in the double blind segment of study PRISMA-3
2. Had an abnormal clinical laboratory value, vital sign, or ECG finding during participation in the main part of the study that, in the opinion of the investigator, was clinically relevant, related to study drug, and would compromise the well-being of the patient in the extension segment
3. Had a clinically significant or unstable medical illness/condition/disorder during the main part of the study that would be anticipated, in the investigator's opinion, to potentially compromise patient safety in the extension segment
4. Is taking or is anticipated to require any prohibited concomitant medication
5. Pregnant, lactating, or breastfeeding
6. Any contraindication for continued IM injections (e.g., treatment with anticoagulant)
7. Inadequate gluteal or deltoid musculature or excessive fat, as determined by the investigator, that would interfere with IM study drug injections
8. Study site personnel and/or persons employed by the investigator or study site or is an immediate family member of such persons

Inclusion Criteria (De Novo Patients):

1. Capable of providing informed consent
2. Age ≥ 18 and ≤ 65 years old
3. On a stable dose of oral risperidone from 4 to 6 mg daily as maintenance therapy for at least the last 4 weeks prior/before screening/baseline and would potentially benefit from conversion to an extended release injectable, in the opinion of the investigator

4. Current diagnosis of schizophrenia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria that is clinically stable as evidenced by:

   • No hospitalizations for acute exacerbations of schizophrenia and psychiatrically stable without significant symptom exacerbation over the last 3 months before screening based on the investigator's judgment
   • PANSS total score < 70 at screening
   • CGI-S score of ≤ 3 (mild) at screening
5. Has previously had a clinically significant beneficial response (improvement in schizophrenia symptoms), as determined by the investigator, to treatment with an antipsychotic medication other than clozapine
6. At least 2 years elapsed since initial onset of active-phase schizophrenia symptoms
7. Subject is outpatient; not hospitalized for worsening of schizophrenia within the last 3 months (hospitalization for social management within this time period is acceptable)
8. Medically stable over the last month prior to screening based on the investigator's judgment
9. BMI of 18.5 to 40.0 kg/m2 (inclusive) at screening
10. Agrees to discontinue prohibited medications as applicable and as clinically indicated according to investigator instructions
11. Dosages of all permitted medications are considered to have been stable (with the exception of medication to be used on an as-needed basis) for ≥ 2 weeks prior to the baseline visit and to remain stable during participation in this study
12. Resides in a stable living situation, in the opinion of the investigator
13. Has an identified reliable informant, in the opinion of the investigator
14. Meets the contraceptive criteria stablished in the study
15. Agrees not to post any personal medical data related to the study or information related to the study on any website or social media site during the study duration.

Exclusion Criteria (De Novo Patients):

1. History of proven inadequate clinical response to treatment with therapeutic doses (with good compliance) of risperidone or paliperidone
2. History of treatment resistance, defined as failure to respond to 2 discrete adequate trials (≥ 4 weeks with an adequate dose) of 2 different antipsychotic medications; history of clozapine use (exception: use was not because of treatment resistance or refractory psychotic symptoms)
3. Known or suspected intolerance of or allergy or hypersensitivity to risperidone, paliperidone, or any of the excipients in the IM formulations of these
4. History of neuroleptic malignant syndrome, clinically significant tardive dyskinesia or tardive dystonia
5. History of any other medical condition that is considered to pose any unjustifiable risk or interfere with study assessments
6. Clinically significant extrapyramidal symptoms at screening or baseline
7. At significant risk of suicidal, homicidal or violent ideation or behavior, by history or as clinically assessed by the investigator at screening visit
8. Answer of "yes" on item 4 or on item 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) (ideation) with the most recent episode occurring within the past 2 months, or answer "yes" to any of the 5 items (behavior) with an episode occurring within the last year
9. Current diagnosis or a history of substance use disorder according to DSM-5 criteria within 6 months prior to the screening visit (with the exception of tobacco, mild cannabis, or mild alcohol use disorder) or a positive drug screen test (with the exception of cannabis) verified by repeat testing
10. Lifetime history of diagnosis of schizoaffective disorder or bipolar disorder
11. Clinically significant comorbid neuropsychiatric disorders
12. Clinically significant or unstable medical illness/condition/disorder that would be anticipated, in the investigator's opinion, to potentially compromise patient safety or adversely affect the evaluation of efficacy
13. Laboratory abnormality that, in the opinion of the investigator, would compromise the well-being of the patient, or any of the following laboratory abnormalities at screening or baseline
14. Pregnant, lactating, or breastfeeding
15. Inadequate gluteal or deltoid musculature or excessive fat, as determined by the investigator, that would interfere with IM study drug injections
16. Any contraindication for IM injections
17. Receipt of any long-acting antipsychotic medication by IM injection within 60 days before screening
18. Current involuntary hospitalization or incarceration
19. Hospitalized for more than 30 days during the 90 days before screening
20. Participation in another clinical study in which the patient received an experimental or investigational drug or agent within 6 months before screening
21. Participation in a clinical study with Risperidone ISM within 12 months before screening
22. Study site personnel and/or persons employed by the investigator or study site or is an immediate family member of such persons
23. Patients taking or anticipated to require any prohibited concomitant medication

Contacts and Locations

Locations

United States, Arkansas

Woodland Research Northwest

Rogers, Arkansas, United States, 72758

United States, California

Collaborative Neuroscience Network, LLC.

Garden Grove, California, United States, 92845

Apostle Clinical Trials Inc.

Long Beach, California, United States, 90813

NRC Research Institute

Orange, California, United States, 92868

CNRI-Los Angeles LLC

Pico Rivera, California, United States, 90660

CNRI-San Diego

San Diego, California, United States, 92112

United States, Florida

Galiz Research

Hialeah, Florida, United States, 33016

Innovative Clinical Research Inc.

Hollywood, Florida, United States, 33021

United States, Maryland

CBH Health LLC

Gaithersburg, Maryland, United States, 20877

United States, Nevada

Altea Research Institute

Las Vegas, Nevada, United States, 89102

United States, New Jersey

Hassman Research Institute

Berlin, New Jersey, United States, 08009

United States, Ohio

Midwest Clinical Research Center

Dayton, Ohio, United States, 45417

United States, Texas

InSite Clinical Research

DeSoto, Texas, United States, 75115

Ukraine

Regional Clinical Hospital n.a I.I. Mechnicov

Dnipro, Ukraine, 49005

Kharkiv Regional Clinical Psychiatric Hospital

Kharkiv, Ukraine, 61068

Public Healthcare Institution "Kharkiv Regional Clinical Psychiatric Hospital No. 3", Center of Urgent Psychiatry

Kharkiv, Ukraine, 61068

Kherson Regional Psychiatric Hospital

Kherson, Ukraine, 73488

Kiev City Psychiatric Hospital No. 2

Kiev, Ukraine, 02192

Kyiv Regional Medical Association "Psykhiatriya" in Kyiv

Kiev, Ukraine, 04080

CI Lviv Regional Clinical Psychiatric Hospital. Department 20

Lviv, Ukraine, 79021

CI Lviv Regional Clinical Psychiatric Hospital. Department 25

Lviv, Ukraine, 79021

Odesa Regional Medical Centre of Mental Health

Odesa, Ukraine, 65006

Maltsev Regional Clinical Psychiatric Ho

Poltava, Ukraine, 36013

N.I. Pyrogov Vinnytsya Natl Medical University

Vinnytsia, Ukraine, 21005

Sponsors and Collaborators

Rovi Pharmaceuticals Laboratories

Investigators

• Principal Investigator: Robert Litman; CBH Health LLC
• Principal Investigator: Yuriy Filts; CI Lviv Regional Clinical Psychiatric Hospital. Department 25

  Study Documents (Full-Text)

Documents provided by Rovi Pharmaceuticals Laboratories:

Study Protocol  [PDF] March 22, 2018

Statistical Analysis Plan  [PDF] February 15, 2019

Informed Consent Form  [PDF] April 13, 2018

More Information

Publications of Results:

Filts Y, Litman RE, Martínez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. Schizophr Res. 2022 Jan;239:83-91. doi: 10.1016/j.schres.2021.11.030. Epub 2021 Nov 27.

• Responsible Party: Rovi Pharmaceuticals Laboratories
• ClinicalTrials.gov Identifier: NCT03870880
• Other Study ID Numbers: ROV-RISP-2016-01_OLE
• First Posted: March 12, 2019
• Results First Posted: February 23, 2022
• Last Update Posted: February 23, 2022
• Last Verified: March 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Risperidone; Serotonin Antagonists; Serotonin Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Physiological Effects of Drugs; Antipsychotic Agents; Tranquilizing Agents; Central Nervous System Depressants; Psychotropic Drugs; Dopamine Antagonists; Dopamine Agents